A Phase I Trial of Dose Dense (Biweekly) Carboplatin Combined With Paclitaxel and Pegfilgrastim (Neulasta): A Feasibility Study in Patients With Untreated Stage III and IV Ovarian, Tubal or Primary Peritoneal Cancer
Overview
- Phase
- Phase 1
- Intervention
- Adjuvant Therapy
- Conditions
- Fallopian Tube Carcinoma
- Sponsor
- Gynecologic Oncology Group
- Enrollment
- 43
- Locations
- 11
- Primary Endpoint
- Number of patients who have greater than or equal to 1 dose-limiting toxicity, assessed by Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
This phase I trial is studying the side effects of giving carboplatin and paclitaxel together with pegfilgrastim in treating patients with stage III or stage IV ovarian epithelial, fallopian tube, primary peritoneal, or carcinosarcoma cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving carboplatin and paclitaxel together with pegfilgrastim after surgery may kill any tumor cells that remain after surgery.
Detailed Description
PRIMARY OBJECTIVES: I. Establish the feasibility of adjuvant dose-dense carboplatin and paclitaxel followed by pegfilgrastim, in terms of absence of grade 3 or 4 nonhematologic toxicities without major dose delays or additional hematological support (e.g., red blood cell or platelet transfusions or admission for febrile neutropenia), in patients with stage III-IV ovarian epithelial, fallopian tube, primary peritoneal cancer, or carcinosarcoma cancer. SECONDARY OBJECTIVES: I. Estimate the percentage of patients who develop ≥ grade 2 peripheral neurotoxicity from this regimen. II. Estimate the clinical response rate in patients with measurable disease treated with this regimen. III. Assess the toxicity of this regimen. OUTLINE: This is a multicenter study. Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2. Treatment repeats every 2 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 1 year.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of 1 of the following:
- •Primary peritoneal carcinoma
- •Fallopian tube carcinoma
- •Ovarian epithelial carcinoma
- •Carcinosarcoma
- •Stage III or IV disease
- •Previously untreated disease, except for mandatory prior surgery
- •No ovarian epithelial carcinoma of low malignant potential (i.e., borderline carcinomas)
- •GOG performance status 0-2
- •Absolute neutrophil count ≥ 1,500/mm³
Exclusion Criteria
- Not provided
Arms & Interventions
Treatment (carboplatin, paclitaxel, pegfilgrastim)
Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.
Intervention: Adjuvant Therapy
Treatment (carboplatin, paclitaxel, pegfilgrastim)
Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.
Intervention: Carboplatin
Treatment (carboplatin, paclitaxel, pegfilgrastim)
Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.
Intervention: Paclitaxel
Treatment (carboplatin, paclitaxel, pegfilgrastim)
Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.
Intervention: Pegfilgrastim
Outcomes
Primary Outcomes
Number of patients who have greater than or equal to 1 dose-limiting toxicity, assessed by Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)
Time Frame: 12 weeks
Secondary Outcomes
- Number of patients with > grade 1 peripheral neuropathy based on the GOG neurotoxicity scale(Up to 1 year)
- Grade of toxicity as assessed by CTCAE v3.0(Up to 1 year)
- Frequency and duration of objective response (complete and partial response) assessed by Response Evaluation Criteria for Solid Tumors (RECIST)(Up to 1 year)